Moreover, mouse models of KRAS-driven pancreatic cancer were shown to be partially dependent on SMYD2 and indicate that genotoxic agents are more effective in the absence of SMYD2 activity. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.